Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tucotuzumab celmoleukin

Drug Profile

Tucotuzumab celmoleukin

Alternative Names: EMD-273066; huKS-IL2; KS-IL2; KS-interleukin-2

Latest Information Update: 29 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EMD Lexigen
  • Developer EMD Lexigen; Merck KGaA
  • Class Antineoplastics; Cytokines; Immunoglobulin fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Aug 2017 EMD Serono terminates a phase II trial in Ovarian cancer because the trial got cancelled and no subjects signed informed consent form in USA (Parenteral) (NCT00408967)
  • 28 Feb 2009 Tucotuzumab celmoleukin is still in phase II development for small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top